Skip to main content
Livermore
Livermore
ZHEN

Ally Bridge Group (NY) LLC

SEC CIK
0001822947
Latest filing
Aug 14, 2026

The latest 13F from Ally Bridge Group (NY) LLC covers Q2 2026 (filed Aug 14, 2026): 23 long positions worth $77.6M. The top 10 holdings make up 64.8% of the portfolio, and the largest is Minerva Neurosciences, Inc. (NERV) at 15.6%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$29.2M
Added
2
Est. +$5.60M
Reduced
9
Est. −$25.8M
Sold out
8
Est. −$39.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. NERVMinerva Neurosciences, Inc.
    15.6%$12.1MHistory
  2. PMNProMIS Neurosciences Inc.
    10.5%$8.16MHistory
  3. TRAXFirst Tracks Biotherapeutics, Inc.
    7.4%$5.72MHistory
  4. AXSMAxsome Therapeutics, Inc.
    5.2%$4.04MHistory
  5. ASMBAssembly Biosciences, Inc.
    5.0%$3.85MHistory

Share of portfolio

Top 5 holdings and the other 18 positions, by share of portfolio value

  1. NERV15.6%
  2. PMN10.5%
  3. TRAX7.4%
  4. AXSM5.2%
  5. ASMB5.0%
  6. Other 18 positions56.4%

Biggest buys

New and added positions, by estimated amount bought

  1. TRAXFirst Tracks Biotherapeutics, Inc.
    +$5.72MNewHistory
  2. AXSMAxsome Therapeutics, Inc.
    +$4.04MNewHistory
  3. ASMBAssembly Biosciences, Inc.
    +$3.85MNewHistory
  4. CLYMClimb Bio, Inc.
    +$3.25MNewHistory
  5. KURAKura Oncology, Inc.
    +$3.18MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. TRAXFirst Tracks Biotherapeutics, Inc.
    +7.37 pp0.0% → 7.4%History
  2. NERVMinerva Neurosciences, Inc.
    +5.65 pp9.9% → 15.6%History
  3. PMNProMIS Neurosciences Inc.
    +5.29 pp5.2% → 10.5%History
  4. AXSMAxsome Therapeutics, Inc.
    +5.20 pp0.0% → 5.2%History
  5. ASMBAssembly Biosciences, Inc.
    +4.96 pp0.0% → 5.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. PRAXPraxis Precision Medicines, Inc.
    −$10.6MSold outHistory
  2. SLNOSoleno Therapeutics Inc
    −$6.70MSold outHistory
  3. OVIDOvid Therapeutics Inc.
    −$5.90MReducedHistory
  4. CMPSCOMPASS Pathways plc
    −$5.78MSold outHistory
  5. TARSTarsus Pharmaceuticals, Inc.
    −$5.67MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PRAXPraxis Precision Medicines, Inc.
    −10.50 pp10.5% → 0.0%History
  2. SLNOSoleno Therapeutics Inc
    −6.65 pp6.7% → 0.0%History
  3. CMPSCOMPASS Pathways plc
    −5.74 pp5.7% → 0.0%History
  4. TARSTarsus Pharmaceuticals, Inc.
    −5.64 pp5.6% → 0.0%History
  5. OVIDOvid Therapeutics Inc.
    −4.05 pp6.2% → 2.2%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$77.6M
−$23.1M (−22.9%) vs. prior quarter
Positions
23
+2 vs. prior quarter
Top 10 concentration
64.8%
Top 10 as share of value
Turnover
39.1%
Q2 2026, one quarter
Average holding period
2.4 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $413.1M (Q1 2021)

Q1 2021: $413.1MQ2 2021: $356.5MQ3 2021: $305.1MQ4 2021: $286.1MQ1 2022: $134.9MQ2 2022: $109.7MQ3 2022: $151.5MQ4 2022: $102.8MQ1 2023: $76.3MQ2 2023: $82.6MQ3 2023: $85.2MQ4 2023: $139.0MQ1 2024: $179.9MQ2 2024: $167.9MQ3 2024: $186.8MQ4 2024: $116.6MQ1 2025: $110.9MQ2 2025: $120.2MQ3 2025: $119.4MQ4 2025: $63.0MQ1 2026: $100.7MQ2 2026: $77.6M
Q1 2021Q2 2026
13F filings of Ally Bridge Group (NY) LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202623$77.6MNERVPMNTRAXvs. Q1 2026SEC
Q1 2026May 18, 202621$100.7MPRAXNERVSLNOvs. Q4 2025SEC
Q4 2025Feb 17, 202613$63.0MABVXSLNOATAIvs. Q3 2025SEC
Q3 2025Nov 14, 202518$119.4MSLNOMDGLATAIvs. Q2 2025SEC
Q2 2025Aug 14, 202524$120.2MVRNASLNOLENZvs. Q1 2025SEC
Q1 2025May 15, 202528$110.9MSWTXVRNASLNOvs. Q4 2024SEC
Q4 2024Feb 14, 202530$116.6MITCITARSINSMvs. Q3 2024SEC
Q3 2024Nov 14, 202429$186.8MINSMTARSMRUSvs. Q2 2024SEC
Q2 2024Aug 14, 202425$167.9MSLNOSRPTGERNvs. Q1 2024SEC
Q1 2024May 15, 202422$179.9MBPMCSLNOCGONvs. Q4 2023SEC
Q4 2023Feb 14, 202422$139.0MARGXSLNOCBAYvs. Q3 2023SEC
Q3 2023Nov 14, 202319$85.2MMLTXXENEITCIvs. Q2 2023SEC
Q2 2023Aug 14, 202317$82.6MRETAVRNAXENEvs. Q1 2023SEC
Q1 2023May 15, 202318$76.3MVRNAXENEBellus Health Inc Newvs. Q4 2022SEC
Q4 2022Feb 14, 202330$102.8MRAREWHWKACADvs. Q3 2022SEC
Q3 2022Nov 14, 202239$151.5MSGENRARESNYvs. Q2 2022SEC
Q2 2022Aug 15, 202222$109.7MARGXMDVLCOGTvs. Q1 2022SEC
Q1 2022May 16, 202221$134.9MLNTHISEEGHvs. Q4 2021SEC
Q4 2021Feb 14, 202230$286.1MNTRAARVNRGENvs. Q3 2021SEC
Q3 2021Nov 15, 202129$305.1MNTRARGENARVNvs. Q2 2021SEC
Q2 2021Aug 16, 202127$356.5MMDVLNTRAFATEvs. Q1 2021SEC
Q1 2021May 17, 202131$413.1MAVIRMDVLCERE–SEC

13D and 13G filings

Companies where Ally Bridge Group (NY) LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Ally Bridge Group (NY) LLC does not currently report owning 5% or more of any company.

Latest filings

6 filings on file made by Ally Bridge Group (NY) LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Ally Bridge Group (NY) LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
WHWKWhitehawk Therapeutics, Inc.Aug 14, 20264:30 PM ETABG Management Ltd.and 12 others13G/A9.40%5.68M shares+3.10 ppfrom 6.30%Jun 30, 2026SEC
PMNProMIS Neurosciences Inc.Feb 5, 20267:02 PM ETABG Management Ltd.and 8 others13D/A17.00%1.64M shares+5.70 ppfrom 11.30%Feb 3, 2026SEC
PMNProMIS Neurosciences Inc.Feb 2, 20264:30 PM ETABG Management Ltd.and 3 others13D/A11.30%6.07M shares0.00 ppfrom 11.30%Jan 29, 2026SEC
PMNProMIS Neurosciences Inc.Oct 29, 20254:30 PM ETABG Management Ltd.and 3 others13D11.30%6.07M shares−0.50 ppfrom 11.80%Oct 22, 2025SEC
PMNProMIS Neurosciences Inc.Aug 4, 20255:55 PM ETABG Management Ltd.and 3 others13G11.80%6.06M sharesNewJul 29, 2025SEC
WHWKWhitehawk Therapeutics, Inc.Mar 10, 20254:30 PM ETABG Management Ltd.and 12 others13G6.30%2.91M sharesNewMar 4, 2025SEC